Market Research Report
Epiomic Epidemiology Series: Atrial Fibrillation Forecast in 19 Major Markets 2020-2030
|Published by||Black Swan Analysis||Product code||342571|
|Published||Content info||76 Pages
Delivery time: 1-2 business days
|Epiomic Epidemiology Series: Atrial Fibrillation Forecast in 19 Major Markets 2020-2030|
|Published: March 20, 2020||Content info: 76 Pages||
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Atrial Fibrillation in 19 Major Markets.
Atrial Fibrillation (AF) is the most prevalent type of supraventricular arrhythmia. AF occurs when abnormal electric signals are sent to the atria, which cause them to contract quickly and irregularly. For many patients, the condition is largely asymptomatic, however when symptoms become bothersome and frequent, intervention is required to restore normal rhythm.
This report provides the current prevalent population for AF across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the classification and patient treatment options for AF. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main patient features and co-morbidities of AF have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.